MX2023005707A - Coagonistas de los receptores de péptido-1 similar a glucagón humano (glp-1) y amilina. - Google Patents

Coagonistas de los receptores de péptido-1 similar a glucagón humano (glp-1) y amilina.

Info

Publication number
MX2023005707A
MX2023005707A MX2023005707A MX2023005707A MX2023005707A MX 2023005707 A MX2023005707 A MX 2023005707A MX 2023005707 A MX2023005707 A MX 2023005707A MX 2023005707 A MX2023005707 A MX 2023005707A MX 2023005707 A MX2023005707 A MX 2023005707A
Authority
MX
Mexico
Prior art keywords
glp
agonists
compound
amylin receptors
pharmaceutical formulation
Prior art date
Application number
MX2023005707A
Other languages
English (en)
Inventor
Christian Wenzel Tornøe
Thomas Kruse
Østergaard Søren
Anne Louise Bank Kodal
Wouter Frederik Johan Hogendorf
Johnny Madsen
Schäffer, (Fallecido) Lauge
Alice Ravn Madsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2023005707A publication Critical patent/MX2023005707A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a un compuesto que comprende un agonista del receptor de GLP-1 y un agonista del receptor de amilina. La invención también se refiere a una formulación farmacéutica, adecuada para, pero sin limitarse a, la administración oral, que comprende tal compuesto. El compuesto y la formulación farmacéutica que lo comprende pueden usarse para el tratamiento médico de sujetos con sobrepeso, obesidad y comorbilidades asociadas.
MX2023005707A 2020-12-18 2021-12-17 Coagonistas de los receptores de péptido-1 similar a glucagón humano (glp-1) y amilina. MX2023005707A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20215291 2020-12-18
EP21154668 2021-02-02
EP21179810 2021-06-16
PCT/EP2021/086494 WO2022129526A1 (en) 2020-12-18 2021-12-17 Co-agonists of the glp-1 and amylin receptors

Publications (1)

Publication Number Publication Date
MX2023005707A true MX2023005707A (es) 2023-07-31

Family

ID=79024591

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005707A MX2023005707A (es) 2020-12-18 2021-12-17 Coagonistas de los receptores de péptido-1 similar a glucagón humano (glp-1) y amilina.

Country Status (12)

Country Link
US (2) US12054528B2 (es)
EP (1) EP4263581A1 (es)
JP (1) JP7554928B2 (es)
KR (2) KR20240074867A (es)
AU (1) AU2021403851A1 (es)
CA (1) CA3201088A1 (es)
CL (1) CL2023001714A1 (es)
CO (1) CO2023008866A2 (es)
IL (1) IL303127A (es)
MX (1) MX2023005707A (es)
PE (1) PE20231659A1 (es)
WO (1) WO2022129526A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102691149B1 (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
AR127945A1 (es) 2021-12-13 2024-03-13 Novo Nordisk As Formulaciones farmacéuticas que comprenden un agonista del receptor de amilina, un agonista del receptor de glp-1 y una ciclodextrina
WO2023187067A1 (en) 2022-03-30 2023-10-05 Novo Nordisk A/S Formulation method
WO2024022465A1 (zh) * 2022-07-29 2024-02-01 杭州九源基因工程有限公司 一种人胰淀素多肽衍生物及其用途
WO2024030934A2 (en) * 2022-08-05 2024-02-08 Indiana University Research And Technology Corporation Glucagon-like peptide-1 receptor antagonists
WO2024179606A1 (zh) * 2023-03-02 2024-09-06 甘李药业股份有限公司 一种glp-1化合物的医药用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0663006A1 (en) 1992-09-30 1995-07-19 Zymogenetics, Inc. Human calcitonin receptor
BRPI0414539B8 (pt) 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
EP2422807A3 (en) 2004-02-11 2012-05-30 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
WO2007109354A2 (en) * 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
CN101868476B (zh) 2007-09-05 2015-02-25 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途
JP5606314B2 (ja) 2007-09-05 2014-10-15 ノボ・ノルデイスク・エー／エス Ａ−ｂ−ｃ−ｄ−で誘導体化されたペプチドとその治療用途
WO2010118384A2 (en) 2009-04-10 2010-10-14 Amylin Pharmaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
EP2504021A4 (en) 2009-11-23 2013-05-15 Amylin Pharmaceuticals Llc POLYPEPTIDE CONJUGATE
PL2513140T3 (pl) * 2009-12-16 2016-04-29 Novo Nordisk As Podwójnie acylowane pochodne glp-1
WO2011084808A2 (en) 2009-12-21 2011-07-14 Amunix Operating Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
EP2714069A4 (en) 2011-05-25 2015-06-24 Amylin Pharmaceuticals Llc LONG-TERM CONJUGATES WITH TWO HORMONES
WO2012160212A1 (en) 2011-05-25 2012-11-29 Camurus Ab Peptide controlled-release formulations
AU2012266269B2 (en) 2011-06-10 2017-04-06 Novo Nordisk A/S Polypeptides
JP6352806B2 (ja) * 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
RU2641198C3 (ru) 2012-03-22 2021-12-10 Ново Нордиск А/С Композиции glp-1 пептидов и их получение
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
CN105377306B (zh) 2013-06-20 2020-03-17 诺和诺德股份有限公司 Glp-1衍生物和其用途
CN104558198A (zh) 2014-07-25 2015-04-29 成都贝爱特生物科技有限公司 GLP-1类似物和amylin类似物的融合蛋白制备及其用途
ES2887370T3 (es) 2014-09-04 2021-12-22 Novo Nordisk As Nuevo agonista del receptor de amilina y calcitonina
US11572398B2 (en) 2014-11-27 2023-02-07 Novo Nordisk A/S GLP-1 derivatives and uses thereof
EP3233898A1 (en) 2014-12-17 2017-10-25 Novo Nordisk A/S Glp-1 derivatives and uses thereof
CN105367664B (zh) * 2015-11-04 2019-09-20 成都贝爱特生物科技有限公司 激活GLP-1受体和Amylin受体双功能作用的融合蛋白制备及其用途
BR102015031283A2 (pt) 2015-12-14 2018-09-18 Univ Rio De Janeiro Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento
ES2828526T3 (es) 2016-11-07 2021-05-26 Novo Nordisk As Esteres activos DCHBS de compuestos PEG y sus usos
CN108424460A (zh) 2017-02-13 2018-08-21 成都贝爱特生物科技有限公司 GLP-1类似物和davalintide类似物的融合蛋白制备及其用途
IL275778B2 (en) 2018-02-02 2023-12-01 Novo Nordisk As Solid compounds that make up glp-1 agonist n-8-2-hydroxybenzoyl salt
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
EP4142695A1 (en) 2020-04-29 2023-03-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine

Also Published As

Publication number Publication date
KR102667196B1 (ko) 2024-05-27
IL303127A (en) 2023-07-01
EP4263581A1 (en) 2023-10-25
WO2022129526A1 (en) 2022-06-23
CL2023001714A1 (es) 2024-01-05
US12054528B2 (en) 2024-08-06
US20230331803A1 (en) 2023-10-19
PE20231659A1 (es) 2023-10-17
TW202227474A (zh) 2022-07-16
KR20240074867A (ko) 2024-05-28
KR20230019499A (ko) 2023-02-08
CO2023008866A2 (es) 2023-10-09
US20240279299A1 (en) 2024-08-22
JP7554928B2 (ja) 2024-09-20
CA3201088A1 (en) 2022-06-23
JP2023553591A (ja) 2023-12-25
AU2021403851A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
MX2023005707A (es) Coagonistas de los receptores de péptido-1 similar a glucagón humano (glp-1) y amilina.
MX2023008854A (es) Agonistas del receptor acoplado a proteinas g (gpcr), composiciones farmaceuticas que los comprenden y metodos para su uso.
TN2011000281A1 (en) Dosage regimen of an s1p receptor agonist
TN2012000002A1 (en) Gpr119 agonists
PL1891038T3 (pl) Podstawione n-arylopirolidyny jako selektywne modulatory receptora androgenowego
NZ746784A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
TW200738269A (en) Oral delivery of therapeutic agents using tight junction agonists
EP1958621A3 (en) Drug detoxification protocol using microdosing
MX2019008006A (es) Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
EE05761B1 (et) Kombineeritud ravimkoostis diabeedi ning ainevahetushäirete raviks
NZ715686A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
MX2023000303A (es) Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
CO6280470A2 (es) Bis-piridilpiridonas como antaginistas del receptor 1 de la hormona concentradora de la melanina
CL2009002017A1 (es) Uso de un agonista de esfingosina-1-fosfato (s1p) derivado de aminopropanodiol para tratar la malaria cerebral; formulacion farmaceutica y forma farmaceutica que comprende el agonista de s1p y un farmaco antimalaria.
ZA202107825B (en) Pharmaceutical parenteral composition of dual glp1/2 agonist
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
CL2008003024A1 (es) Compuestos derivados de alquilsulfonilbenzotiazol, moduladores del receptor de grelina; formulacion farmaceutica; y uso para el tratamiento de obesidad o sobrepeso, diabetes, sindrome metabolico, entre otras.
WO2011011847A8 (en) Pharmaceutical composition for treating medical conditions and a method for treating alimentary disorders and related diseases
MX2023000403A (es) Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del peptido insulinotropico dependiente de glucosa (gip).
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
ZA202301635B (en) Ham15-52 analogues with improved amylin receptor (hamy3r) potency
JP2020109065A (ja) 食欲不振改善用組成物
MX2021015930A (es) Composiciones farmaceuticas para peptidos co-agonistas de glucagon y glp-1.
CO2024006689A2 (es) Formulaciones farmacéuticas que comprenden una ciclodextrina
AR127945A1 (es) Formulaciones farmacéuticas que comprenden un agonista del receptor de amilina, un agonista del receptor de glp-1 y una ciclodextrina